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Abstract
Corydalis yanhusuo. W.T. extracts (YHS) are widely used for the treatment of pain and
inflammation. There are a few studies that assessed the effects of YHS in pain assays; how-
ever, none of these studies has systematically compared its activities in the different pain
animal modes namely: acute, inflammatoryand chronic pain. Furthermore, little is known
about the mechanism of YHS activity in these assays. The aim of this study was to system-
atically evaluate the antinociceptive propertiesof YHS by testing it in four standardized pain
assays and to investigate its mechanism. YHS antinociceptive propertieswere analyzed in
the tail flick, the formalin paw licking, the von Frey filament and the hot box assays after spi-
nal nerve ligation, which monitors acute nociceptive, persistent inflammatoryand chronic
neuropathic pain, respectively. YHS pharmacological profile was determinedby screening
it against a battery of G-protein coupled receptors and its mechanism of action was studied
using knock-out mice. Our study shows that YHS, at a non-sedative dose, increases the tail
flick latency in the tail flick assay without resulting in development of tolerance. YHS also
decreases paw licking time in the formalin assay. Further, YHS increases paw withdraw
threshold and latency in the von Frey filament and the hot box assays, respectively. In vitro,
YHS exhibits prominent dopamine receptor antagonistic properties. In dopamine D2 recep-
tor knockout mice, its antinociceptive effects are attenuated in acute and neuropathic pain
but not inflammatorypain assays. Our results therefore indicate that YHS effectively attenu-
ates acute, inflammatoryand neuropathic pain, without causing tolerance. The effects on
acute and neuropathic pain, but not inflammatorypain, are at least partiallymediated
through dopamineD2 receptor antagonism. Since YHS is a dietary supplement commer-
cially available in the United States, our data suggest that it might be a candidate for alterna-
tive pain treatment.
PLOSONE | DOI:10.1371/journal.pone.0162875 September 13, 2016 1 / 15
a11111
OPENACCESS
Citation:Wang L, Zhang Y, Wang Z, Gong N, Kweon
TD, Vo B, et al. (2016) The Antinociceptive Properties
of the Corydalis yanhusuoExtract. PLoS ONE 11(9):
e0162875. doi:10.1371/journal.pone.0162875





Copyright:© 2016Wang et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricteduse, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement:All relevant data are
within the paper and its Supporting Information files.
Funding: This work was supported by National
Institutes of Health grant DA024746 and Eric L. and
Lila D. Nelson Chair in Neuropharmacology awared
to OC. This work is also supported by the Center for
Autism Research and Translation (CART), which is
supported by the William & Nancy Thompson Family
Foundation. The recipient is OC. This work was also
supported by the Key Program of National Natural
Science Foundation of China 21135005 awarded to
XL and 81402806 awarded to YZ and the Major
Project of National High Technology Research and
Introduction
Pain is an unpleasant sensory and emotional experience associated with tissue damage [1].
Pain management is currently limited, particularly for chronic pain. The potent opiate drugs
are common and effective against some types of moderate to severe pain [2]. This class of drug,
however, causes severe side effects [3, 4]. Anticonvulsants, antidepressants and selective seroto-
nin noradrenaline reuptake inhibitors are used, but not exclusively, for neuropathic pain treat-
ment with limited effectiveness [5]. Therefore, new analgesic alternatives are still being
explored and pursued with every effort.
For centuries, varieties of extract from natural products, mostly plants, have been used for
pain relief. Corydalis yanhusuo. W.T. Wang is officially listed in the Chinese Pharmacopoeia
and its powder and decoctionhave been widely used for treatment of pain and inflammation
[6]. However, only a few studies have investigated YHS antinociceptive properties in rodents
assessed by standardized pain assays. None of the studies addressed concomitantly YHS effects
in acute, inflammatory and neuropathic pain. Also these studies report large variations with
respect to number of administrations (either single, 3 days or 5 days administration) and dos-
age (ranging from 30 mg/kg to 20 g/kg). Furthermore none of these studies addressed the
mechanism of YHS effect [7–10]. YHS is known to contain several alkaloids [11–14]. However
only l-tetrahydropalmatine (l-THP) and dehydrocorybulbine (DHCB) have been isolated and
quantified in YHS. Both alkaloids display antinociceptive properties which rely at least par-
tially, on dopamine D2 receptor antagonism [15, 16]. Therefore, we systematically evaluated
the antinociceptive properties of YHS in three animal models of pain assays and investigated
its pharmacological profile and mechanism of action.
Materials andMethods
Plant material and extraction
The tuber of Corydalis yanhusuo W.T. Wang was collected in Dongyang County (Zhejiang,
China) and authenticated by Institute of Medication, XiyuanHospital of China Academy of
Traditional ChineseMedicine. The tuber was first processed with vinegar as used in the tradi-
tional way to enhance the analgesic effect. The extraction of YHS was performed by Mai-Di
Hai Pharmacy (China). The procedures were as follows: 10 kg of herb was ground into powder
and decocted in 100 L of water at 100°C for 120 minutes. Then the residue was collected and
redecocted in 100 L of water at 100°C for 90 minutes. The decoctionswere pooled together and
dried by spray drying to yield 0.6 kg water extract.
Plasmid constructionand stable cell lines
All G protein coupled receptors (GPCRs) used in this study were amplified from human
cDNA library (Clontech, Palo Alto, CA) and cloned into pcDNA 3.1 (-) (Invitrogen, Carlsbad,
CA). The sequences were confirmed by sequencing from both ends and with internal primers
by Laragen (Los Angeles, CA). Human embryonic kidney-293 T cells (HEK293T) were cul-
tured in Dulbecco’s Minimum Essential Medium (DMEM) supplemented with 10% fetal
bovine serum (FBS). Serotonin 1A, 2A, 2C, adrenergic α1B, α2A, α2B, β1, β2 and neuokinin 1
receptors were transiently expressed in HEK293T cells. Briefly, plasmids were transfected into
HEK293T cells with jetPRIME transfection reagents (Polyplus-transfection) following the
manufacturer's recommendation. Three μg of each of the receptor and G protein chimera
(either Gα15 or Gqαi3) were mixed in 750 ul of jetPRIME buffer and let stand at room temper-
ature for 10 minutes after mixing with 12 μl of the transfection reagent. The mixture was added
to cells without changing medium. The stable cell lines expressing dopamine D1, D2,
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muscarinic acetylcholine 1, histamine 2, melanin concentrating hormone 1, melatonin 1,
opioid μ, δ and κ receptors were created individually. As an example, the stable cell lines
expressing human opioid μ, δ or κ receptors were created as previously reported [17]. Briefly,
the individual human opioid receptors μ, δ, or κDNA plasmid were cotransfectedwith Gqαi3.
Transfection was carried out with lipofectamine (Invitrogen, Carlsbad, CA) using the protocol
provided by the supplier. Stable cell clones were selected in the presence of 200 μg/ml G418,
200 μg/ml hygromycin and 200 μg/ml zeocin.
Fluorometric Imaging Plate Reader Assay (FLIPR)
The assay was performed as reported earlier [18]. Briefly, the stable cells were seeded into poly-
D-lysine-coated black wall, clear-bottom 96-well plates at a density of 80,000 cells per well.
Twenty-four hours later the mediumwas removed and replaced with 100 μl of dye loading
solution (2 μM Fluo-4 AM dissolved in FLIPR buffer, which consists of pluronic acid in
1×Hank’s buffer supplemented with 20 mMHEPES, pH 7.4) for one hour at 37°C. The cells
were then washed three times with FLIPR buffer prior to FLIPR assay. The samples, which
were re-dissolved in dimethyl sulphoxide (DMSO) and stored in 96-well drug plates, were
diluted with FLIPR buffer and then added into the cells within 4s automatically. For agonist
tests, the intracellular Ca2+ concentration was monitored at 520 nm with excitation wavelength
at 488 nm over a period of 4 minutes. For antagonist tests, the compound was first incubated
with the cell for 10 minutes, before the addition of intrinsic receptor ligand with EC50 deter-
mined in individual receptor expressing cell lines. Data were expressed as fluorescence (arbi-
trary units) versus time.
Animals
Male Swiss Webster mice (age 8–12 weeks, Charles River, Wilmington, MA) were used in the
tail flick, formalin, locomotion and rotarod assays. Male 129/sv mice (age 8–12 weeks, Charles
River, Wilmington, MA) were used in the von Frey filament, hot box and locomotion assays.
Male dopamine D2 receptor knockout mice (age 8–12 weeks) were used for mechanistic stud-
ies (tail flick, formalin, von Frey filament, hot box, locomotion and rotarod assays). Age-
matched wild-type littermates with the same genetic background were used as control animals.
The generation of dopamine D2 knockout mice was reported previously [19]. Mice were
group-housed and maintained on a 12-hours light/dark cycle (light on at 7:00am) with food
and water available ad libitum. All experimental procedures were approved by the Institutional
Animal Care and Use Committee of University of California, Irvine and were performed in
compliance with national and institutional guidelines for the care and use of laboratory ani-
mals. Apart from the daily monitoring of common animal health, animals that were subjected
to the tail flick and hot box assays were monitored for potential tissue injury. Animals with tis-
sue injury after the assays were excluded from further assessment. Animals that were subjected
to the formalin paw assay were euthanized with CO2 overdose followed by cervical dislocation
immediately after the assessment to alleviate inflammation induced distress.
DrugAdministrations
YHS was dissolved in a vehicle solution of cremophor EL: ethanol: saline (2:1:17). Morphine
sulphate (Sigma-Aldrich)was dissolved in saline. Dehydrocorybulbine (DHCB) was synthe-
sized as previously reported [16] and dissolved in saline. L-tetrahydropalmatine (l-THP, Xi,an
XiaocaoBotianical Development Co.,LTD) was dissolved in saline. YHS (100, 200, 250, 500
mg/kg, i.p., 5 ml/kg) and morphine (10 mg/kg, i.p., 5 ml/kg) were administered at different
time points depending on the assays described in detail below. We also compared YHS efficacy
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to that of a mixture of l-THP and DHCB. YHS contains approximately 0.25% of l-THP and
0.18% of DHCB [16]. Therefore, a 500 mg/kg YHS administration (i.p., 5 ml/kg) was compared
to the administration of a mixture of 1mg/kg l-THP (i.p., 5 ml/kg) and 1mg/kg DHCB (i.p., 5
ml/kg) in the tail flick assay. Both Solutions were administered 30 minutes before the assay.
Behavioral Testing
Tail-flick assay. The tail-flick assay was performed as described before [16]. Briefly, the
tail removal latency was measured using an electronically controlled tail-flick analgesimeter
(UGO basile biological research apparatus, 7360 Tail Flick) that integrated both a thermal noci-
ceptive stimulus and an automated response timer. Mice were applied with a thermal stimulus
(focused light from a 20W infrared bulb as the heat source) directed to the tips of their tails.
The time from onset of stimulation to a rapid withdrawal of their tails from the heat source
was recorded as tail flick latency. These experiments were carried out using a moderate 6–7 sec-
onds of baseline to permit low antinociception detection. A maximum of 22 seconds was set as
a cut off time to prevent tissue damage. After three consecutive daily baselinemeasurements,
mice were administered with vehicle, morphine (10 mg/kg), YHS (100–500 mg/kg) or the mix-
ture of DHCB (1 mg/kg) and l-THP (1 mg/kg) and tail flick latency was measured immediately
before the injections and 30, 60, 120 and 180 minutes after the injection.
Formalin paw assay. The formalin paw assay was performed as described before [20].
Briefly, mice were placed individually in a 4 liter glass beaker and were allowed to acclimate for
30 minutes before the test. Vehicle, morphine (10 mg/kg), or YHS (200 mg/kg) were adminis-
tered 15 minutes prior to formalin injection. Twenty five μl of 0.5% formalin solution was
administered into the dorsal surface of the right hind paw using a 50 μl Hamilton syringe with
a 30 gauge needle. Immediately after formalin injection,mice were placed individually in the
beaker and a mirror was arranged at a 45° angle under the beaker to allow clear observation of
the paws. The nociceptive behavior (paw licking) was observed continuously for 50 minutes.
The time animals spent licking the injected paw during the first phase (0–10 minutes) and sec-
ond phase (10–50 minutes) were recorded in a 5-minute intervals.
Spinal nerve ligation (SNL) surgery. Unilateral SNL injury was performed as described
before [21]. Briefly, the left L4 spinal nerve [22] was exposed in an isoflurane anesthetized
mouse and ligated with a silk suture between dorsal root ganglia and the conjunction of sciatic
nerve. Sham operations were performed in the same way except that spinal nerves were not
ligated. The drug administration was carried out about two weeks post SNL when all experi-
mental mice have developed hindpaw mechanical and thermal hypersensitivities on the injured
side, assessed by the von Frey filaments and hot box assay, respectively.
Von Frey filaments assay. Paw withdrawal thresholds (PWT) to calibrated von Frey fila-
ment (Stoelting,Wood Dale, IL) stimulation were assessed in both hindpaws with a modified
up-downmethod of Dixon [23] before and after SNL as describedpreviously [24]. Briefly,
mice were acclimated for 60 minutes on a mesh surface of the test apparatus. Mice were then
administered vehicle or YHS (200 mg/kg). A series of von Frey filaments (buckling force
between 0.04 and 2.0 g), starting with 0.4 g, was applied to the hindpaw plantar surface before
the injection and 60, 120 and 240 minutes after the injection. A positive response of paw lifting
within 5 seconds led to the use of the next weaker filament. Absence of paw lifting after 5 sec-
onds was considered a negative response and led to the use of the next filament with increasing
force. Scores of six measurements, starting from the one prior to the first positive response,
were used to calculate the 50% PWT except that a score of 0.01 g was assigned to four consecu-
tive positive responses or a score of 3.0 g was assigned to three consecutive negative responses.
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Hargreaves assay. Mouse hindpaw withdrawal latencies (PWL) from a thermal stimulus
were measured in a modifiedHargreaves-type hot box as describedbefore [25]. Briefly, mice
were acclimated for at least 60 minutes within individual boxes on the hot box glass surface
maintained at 30°C (developed by University of California, San Diego).Mice were then admin-
istered vehicle or YHS (200 mg/kg). A radiant light source under the glass surface was aligned
to the hindpaw plantar surface before the injection and 60, 120 and 240 minutes after the injec-
tion. A timer was activated when the light source was turned on and stopped when a paw with-
drawal from the light source was detected by motion sensors or at 20 seconds of light
stimulation to prevent thermal injury.
Tolerance assay. The tolerance study was performed using a repeated-injection schedule
as described before [26]. Mice were administered with vehicle, morphine (10 mg/kg), or YHS
(200 mg/kg) once daily for consecutive 7 days. The loss of the antinociceptive effects of drugs
in the tail-flick test was used to assess the degree of tolerance. The procedure of the tail flick
assay was described above in the “Tail-flick assay” section. The tail-flick latency was assessed
on the 1st, 3rd, 5th and 7th day, 30 minutes after the injection.
Spontaneous locomotor activity assay. The sedative effects of the drugs on the animals
were evaluated by measuring the spontaneous locomotor activity for 60 minutes as previously
reported [27]. The habituation step was skipped because of the possible sedative effect of the
test drugs. Thirty minutes after mice were administered with vehicle or YHS (100–500 mg/kg),
they were placed into an open field test chamber (40 x 40 cm,Med Associates, inc.). Horizontal
movements were measured by the infrared beams arrays. The total distance animals travelled
for 60 minutes was recorded, analysized and calculated by Activity Monitor 5 software (Med
Associates, inc.); it is used to evaluate the effects of drugs on locomotion.
Rotarod assay. The rotarod assay was performed as described before with modifications
[28]. Mice were trained to remain on the rotarod apparatus (TSE Systems, Inc.) before the test
session for two consecutive days, two trials per day (9:00 am and 3:00 pm). The first training
trial consisted of a 5 minute interval followed by an accelerating speed ranging from 4–20 rota-
tions per minute (rpm) for 180 seconds and then at constant speed at 20 rpm for 120 seconds.
The other three trials consisted of only constant speed at 20 rpm for 120 seconds. Animals
which could easily stay on the rod for at least 60 seconds were used. On the third day, mice
were placed on the rotarod 60 minutes after treatment with vehicle or YHS (100–500 mg/kg),
and the latency to fall off the rotarod within 120 seconds was recorded automatically by an
infrared beam located below the rotating rod.
Data analysis
Graphpad Prism (GraphPad Software, Inc.) was used for statistical analysis. Data are presented
as means ± S.E.M. Results were analyzed by student’s t test or ANOVA followed by the appro-
priate post hoc comparisons, and P< 0.05 was considered statistically significant.
Results
The antinoceceptive propertiesof YHS
The antinociceptive properties of YHS were first tested in the tail-flick assay, which records
responses to an acute thermal stimulus. The results show that YHS significantly increased the
tail flick latencies in a dose dependent manner for a minimum of 3 hours (P< 0.05, Fig 1A).
Noteworthy, two active components of YHS, l-THP and DHCB exhibited antinociceptive
effects with a minimum dose of 10 mg/kg [16]. As mentioned in the method section, 500 mg of
YHS contains approximately 1 mg of l-THP and 1 mg of DHCB. We show that YHS at 500
mg/kg displays a significant antinociceptive effect (P< 0.001, Fig 1B), while a mixture of
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Fig 1. Antinociceptive effects of YHS in acute, inflammatory and neuropathic painmodels. (A) Antinociceptive effects of
YHS (100–500mg/kg) in the tail flick assay (n = 7–9). Two way ANOVA revealed significant drug effects (F6,49 = 38.26,
P < 0.0001), time effect (F4,196 = 59.93, P < 0.0001) and drug x time interaction (F24,196 = 14.15, P < 0.0001) followed by
Bonferroni post hoc test: drug vs vehicle, *P < 0.05, **P < 0.01, *** P < 0.001. (B) Comparison between YHS (500mg/kg) and
themixture of l-THP (1mg/kg) and DHCB (1mg/kg) in the tail flick assay (n = 8–9). Tail-flick latencies were measured60 min
following drug administration. One way ANOVA revealed a significant drug effect (F2,22 = 42.85, P < 0.0001) followed by
Bonferroni post hoc test: drug vs vehicle, *** P < 0.001, N.S., not significant; YHS vs L-THP+DHCB, ### P < 0.001. (C) Time
course of the antinociceptive effects of YHS (200mg/kg) in the formalin paw licking assay (n = 6–7). Two way ANOVA revealed
significant drug effects (F2,17 = 36.59, P < 0.0001) and time effect (F9,153 = 10.22, P < 0.0001) followed by Bonferroni post hoc
test: drug vs vehicle, *P < 0.05, **P < 0.01, *** P < 0.001. (D) Cumulative effects of the antinociceptive effects of YHS (200
mg/kg) in the formalin paw licking assay (n = 6–7). One-way ANOVA indicated significant drug effects in both Phase I (F2,17 =
34.92, P < 0.0001) and Phase II (F2,17 = 31.68, P < 0.0001) followed by Dunnett’s post hoc tests: drug vs vehicle, **P < 0.01,
*** P < 0.001. (E) Antinociceptive effects of YHS (200mg/kg) in the von Frey filament assay after spinal nerve ligation (n = 10).
Two way ANOVA revealed a significant treatment effect (F3,36 = 11.42, P < 0.0001) followed by Bonferroni post hoc test:
contralateral vs. ipsilateral,*** P < 0.001. (F) Antinociceptive effects of YHS (200mg/kg) in the hot box assay after spinal
nerve ligation (n = 10). Two way ANOVA revealed a significant treatment effect (F3,36 = 31.06, P < 0.0001) and drug x time
interaction (F9,108 = 3.045, P = 0.0028) followed by Bonferroni post hoc test: *P < 0.05, *** P < 0.001.
doi:10.1371/journal.pone.0162875.g001
Corydalis and Analgesia
PLOSONE | DOI:10.1371/journal.pone.0162875 September 13, 2016 6 / 15
l-THP and DHCB at 1 mg/kg had no effect (P> 0.05, Fig 1B), possibly indicating that other
components in YHS are necessary for full antinociceptive activity. Most analgesics possess sed-
ative properties, and strong sedationmay mask the assessment of pain. Thus, YHS was tested
for its potential sedative properties by using locomotor activity and rotarod assays. The results
show that up to 200 mg/kg YHS did not significantly reduce locomotor activity nor affect
rotarod (P> 0.05, S1A and S1B Fig). We consequently used 200 mg/kg as the nonsedative
effective dose in the subsequent studies.
We extended our study to evaluate the antinociceptive properties of YHS in the formalin
paw assay, which measures both acute and chronic inflammatory responses [29]. As shown in
Fig 1C and 1D, YHS at 200 mg/kg significantly reduces the time mice spent licking the paw in
both the early phase which corresponds to acute neurogenic pain (P< 0.01), and the late phase
which corresponds to inflammatory pain (P< 0.01). YHS was further tested on animals after
SNL in the von Frey filament and hot box assays, which measure mechanical allodynia and
thermal hyperalgesia respectively. We show that YHS at a non-sedative dose (200 mg/kg, deter-
mined in S1C Fig) significantly increases PWT and PWL in the von Frey filament and hot
box assays, respectively, for a minimum of 2 hours (P> 0.05, Fig 1E and 1F). Mice treated with
vehicle show no effect on either assays (data not shown). Taken together, these data demon-
strate that at a non-sedative dose, YHS is effective in suppressing nociceptive responses to ther-
mally induced acute pain, chemically induced inflammatory pain as well as injury induced
neuropathic pain.
Themechanismof YHS antinociceptive activity
We then investigated the potential mechanism of YHS antinociceptive effects. YHS was first
screened against a battery of GPCRs using the FLIPR assay. As summarized in Table 1, YHS
exhibits antagonistic properties mostly to dopamine D1 and D2 receptors (dose response
curves shown in S2 Fig). The Dopamine D2 receptor has been proposed to play an important
role in pain and analgesia [30]. Besides, l-THP and DHCB have been previously shown to exert
their antinociceptive effects partially through D2 receptor antagonism [15, 16]. Therefore, we
tested whether dopamine D2 receptor is involved in YHS antinociception by using dopamine
D2 receptor knockout (D2KO) mice.
In the tail flick assay, YHS at a non-sedative dose (200 mg/kg, determined in S1D and S1E
Fig), induces antinociceptive effect in wild type (WT, P< 0.001, Fig 2A) but not in D2KO mice
Table 1. Pharmacological profiles of YHSwithinG protein coupled receptors (GPCRs).
CNS Target YHS Activity
Dopamine D1 3.129 ± 0.2423 (Antagonism)
Dopamine D2 3.091 ± 0.1893 (Antagonism)
Serotonin 1A/2A/2C/6 None
Adrenergic α1B/α2A/α2B/β1/β2 None
Muscarinic Acetylcholine R1 None
HistamineR2 None
MelatoninR1 None
Opioid μ, δ, κ None
Opioid receptor-like R None
Melanin concentrating hormoneR1 None
Neurokinin R1 None
IC50 (μg/ml) values are presented as mean±S.E.M.
doi:10.1371/journal.pone.0162875.t001
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(P> 0.05, Fig 2A). In the formalin assay, however, YHS at 200 mg/kg induces a similar level of
antinociceptive responses in bothWT and D2KO mice (P< 0.05, Fig 2B) with no significant
difference (P> 0.05, Fig 2B). These results indicate that the antinociceptive effect of YHS in
acute pain but not inflammatory pain is attenuated in D2KO mice.
In the von Frey filament assay (after SNL), YHS at 200 mg/kg shows antinociceptive effect
(compared between contralateral and ipsilateral paws) inWT (P> 0.05, Fig 3A) but not in
D2KO mice (P< 0.05, Fig 3B). Compared to WTmice, D2KO mice treated with YHS show a
Fig 2. Effects of YHS in D2KOmice assessed in the tail flick and formalin paw licking assays. (A)
Effects of YHS (200mg/kg) in D2KO mice assessed in the tail flick assay (n = 10). Tail-flick latencieswere
measured 120min following drug administration. One-way ANOVA indicated a significant drug effect (F3,36 =
12.53, P < 0.0001) followed by Bonferroni post hoc test: YHS vs vehicle, *** P < 0.001, N.S., not significant;
KO vsWT, ## P < 0.01. (B) Effects of YHS (200mg/kg) in D2KO mice assessed in the formalin paw licking
assay (n = 6). One-way ANOVA indicated significant drug effects in both Phase I (F3,20 = 8.751, P = 0.0007)
and Phase II (F3,20 = 19.01, P < 0.0001) followed by Bonferroni post hoc test: YHS vs vehicle, *P < 0.05,
**P < 0.01, *** P < 0.001; KO vsWT, N.S., not significant.
doi:10.1371/journal.pone.0162875.g002
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significant increase of the PWT difference between contralateral and ipsilateral paws (P< 0.05,
Fig 3C, derived from the difference between the contralateral and ipsilateral paws in terms of
PWT and PWL values within each genotype, respectively), which indicates an attenuated anti-
nociceptive effect of YHS in D2KO mice. In the hot box assay, YHS at 200 mg/kg induces anti-
nociceptive effects (compared between contralateral and ipsilateral paws) in bothWT
(P< 0.05, Fig 3D) and D2KO mice (P< 0.001, Fig 3E). Compared toWTmice, D2KO mice
treated with YHS show an increase of the PWL difference between contralateral and ipsilateral
Fig 3. Effects of YHS in D2KOmice assessed in the von Frey filaments and hot box assays. (A) Effects of YHS (200mg/kg) in WT
mice assessed in the von Frey filaments assay after SNL (n = 10). Paw withdraw thresholdswere measured 60minutes after drug
administration. Two way ANOVA revealed a significant treatment effect (F3,36 = 12.81, P < 0.0001) and time effect (F1,36 = 7.244,
P = 0.0107) followed by Bonferroni post hoc test: contralateral vs. ipsilateral, **P < 0.01, *** P < 0.001, N.S., not significant; YHS vs
vehicle, # P < 0.05. (B) Effects of YHS (200mg/kg) in D2KO mice assessed in the von Frey filaments assay after SNL (n = 10). Paw
withdraw thresholdswere measured 60minutes after drug administration. Two way ANOVA revealed a significant treatment effect (F3,36 =
17.00, P < 0.0001) and time effect (F1,36 = 6.340, P = 0.0164) followed by Bonferroni post hoc test: contralateral vs. ipsilateral,*P < 0.05,
**P < 0.01; YHS vs vehicle, # P < 0.05, N.S., not significant. (C) Paw withdraw threshold (PWT) difference between contralateral (Contra)
and ipsilateral (Ipsi) paws inWT and D2KO mice assessed in the von Frey filaments assay 60minutes after YHS (200mg/kg)
administration (n = 10): t = 2.281,P = 0.0349. Unpaired student t test, KO vsWT, *P < 0.05. (D) Effects of YHS (200mg/kg) in WTmice
assessed in the hot box assay after SNL (n = 10). Paw withdraw latencies weremeasured 60 minutes after drug administration. Two way
ANOVA revealed a significant treatment effect (F3,36 = 66.27, P < 0.0001), time effect (F1,36 = 34.40, P < 0.0001) and drug x time interaction
(F3,36 = 19.38, P < 0.0001) followed by Bonferroni post hoc test: contralateral vs. ipsilateral,*P < 0.05, *** P < 0.001; YHS vs vehicle,
### P < 0.001, N.S., not significant. (E) Effects of YHS (200mg/kg) in D2KO mice assessed in the hot box assay after SNL (n = 9–10). Paw
withdraw latencies were measured 60minutes after drug administration. Two way ANOVA revealed a significant treatment effect (F3,34 =
75.99, P < 0.0001), time effect (F1,34 = 25.25, P < 0.0001) and drug x time interaction (F3,34 = 6.119, P = 0.0019) followed by Bonferroni post
hoc test: contralateral vs. ipsilateral,*** P < 0.001; YHS vs vehicle, ### P < 0.001, N.S., not significant. (F) Paw withdraw latency (PWL)
difference between contralateral (Contra) and ipsilateral (Ipsi) paws inWT and D2KO mice assessed in the hot box assay 60minutes after
YHS (200mg/kg) administration (n = 9–10): t = 1.394,P = 0.1812. Unpaired student t test, N.S., not significant.
doi:10.1371/journal.pone.0162875.g003
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paws, though not statistical significant (P> 0.05, Fig 3F, derived from the difference between
the contralateral and ipsilateral paws in terms of PWT and PWL values within each genotype,
respectively).
Taken together, these data indicate that the antinociceptive effects of YHS are mediated, at
least partially, through dopamine D2 receptor in acute and neuropathic pain, but not in inflam-
matory pain.
Lack of antinociceptive tolerance of YHS extract
Because one of the major drawbacks of the narcotic analgesics is the development of tolerance,
we tested YHS for the development of tolerance to its antinociceptive effect.We show that
unlikemorphine (P< 0.01, Fig 4) YHS does not result in development of tolerance after daily
administration for seven consecutive days (P> 0.05, Fig 4).
Discussion
Pain can be classified into different types: nociceptive pain activated by noxious physical stimu-
lus, inflammatory pain activated by the immune system upon tissue injury and neuropathic
pain caused by damage to the nervous system resulting from physical damage or disease affect-
ing the somatosensory system [1]. Our study is the first to systematically evaluate the antinoci-
ceptive properties of YHS in three types of pain assays (Fig 1). We show that YHS does not
result in development of antinociceptive tolerance after 7 days of once-daily administration
(Fig 4). We further characterized the pharmacological profile of YHS (Table 1) and demon-
strated that antinociceptive effects of YHS are partially attributed to the interaction with dopa-
mine D2 receptor in acute and neuropathic pain, but not inflammatory pain (Figs 2 and 3).
Fig 4. Lack of antinociceptive toleranceof YHS (200mg/kg) in the tail flick assay (n = 7–8). Two way
ANOVA revealed a significant drug effect (F2,19 = 68.24, P < 0.0001), time effect (F4,76 = 19.16, P < 0.0001)
and drug x time interaction (F8,76 = 7.509, P < 0.0001) followed by Bonferroni post hoc test: drug vs vehicle,
*P < 0.05, **P < 0.01, *** P < 0.001. One way ANOVA revealed a significant time effect in morphine treated
group (F3,24 = 5.520, P = 0.005) but not in YHS treated group (F3,28 = 0.6032, P = 0.6184) followed by
Dunnett’s post hoc tests: Day 3,5,or 7 vs Day 1, ## P < 0.01, ### P < 0.001, N.S., not significant.
doi:10.1371/journal.pone.0162875.g004
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Our study confirmed the antinociceptive effects of YHS in the tail flick and the formalin
paw licking assays, but also in the von Frey filament and the hot box assays after spinal nerve
ligation, which monitor acute, inflammatory and neuropathic pain sensations, respectively.
Besides, we show that YHS exhibits more antinociceptive efficacy than its two active compo-
nents l-THP and DHCB. This suggests that YHS contains other active components which com-
bine to produce its analgesic activity. Indeed several alkaloids other than l-THP and DHCB
have been identified in YHS [11–14]. Among these, berberine, palmatine, columbamine and
glaucine, identified in plant extracts others than YHS, have been reported to display antinoci-
ceptive properties in rodents [31–35]. These studies support our suggestion that the additive or
synergistic effects of all these alkaloids, and also other unidentified active components, give
YHS its advantageous antinociceptive property. Moreover, we show that repeated YHS admin-
istration does not lead to development of tolerance and therefore YHSmay present advantages
over morphine in chronic pain treatment.
To better understand the mechanism of the antinociceptive effects of YHS, we screened
YHS against a number of GPCRs. Herb extracts, which contain varieties of compounds, often
exhibit multiple receptor activities. In our screening which covered 20 receptors, YHS exhibited
activities only at dopamine D1 and D2 receptors and these were antagonistic activities. This is
in line with the antagonistic activities of its most studied components l-THP and DHCB [15,
16]. Based on these results, we investigated YHS activity on dopamine receptors in vivo.
Our study shows that in D2KO mice, the antinociceptive effects of YHS are significantly
decreased in acute and neuropathic pain assays. These results indicate that its actions are par-
tially mediated through the blockade of the dopamine D2 receptor. A central role of dopami-
nergic transmission in modulating pain perception within supraspinal and spinal regions has
been demonstrated [30]. Striatal or spinal cord level of dopamine D2 receptor stimulation has
been shown to exhibit antinociceptive effects in acute pain [36–38] and neuropathic pain [39–
42]. These seemingly contradictory results could be explained by the preferential presynaptic
D2 autoreceptor activation of some of the D2 receptor antagonists. It has been reported that a
variety of D2 receptor antagonists at doses lower than that required for antipsychotic effects
results in an increase in dopamine metabolism [43]. Low doses of amisulpride, a selective
antagonist of the D2/D3 receptor with selective preference for presynaptic autoreceptors, show
antinociceptive effects in acute pain assays [44]. Moreover, l-THP and DHCB have also been
shown to exert their antinociceptive effects, at least partially, through D2 receptor antagonism
[15, 16]. Additional studies are needed to determine if the antinociceptive effects of YHS in
acute and neuropathic pain are regulated by presynaptic D2 receptors. Studies have shown that
both D1 and D2 receptors are involved in mediating inflammatory pain responses in rodents
[45–47]. Our study shows that the antinociceptive effect of YHS is not affected in D2KO mice.
In this respect, whether or not the D1 receptor mediates YHS effects in inflammatory pain
needs further investigation.
Consistent with our previous study [16], the D2KO mice display similar tail flick latency
baseline as compared toWTmice in the tail flick assay (data not shown). WT and D2KO mice
also display similar baseline in time spent licking in the formalin assay (Fig 2B). Our study is
the first to characterize the neuropathic pain development after SNL in D2KO mice. It has
been reported that under baseline conditions, D2KO mice show slightly longer PWL in the hot
box assay. These mice are, however, slightly more sensitive to mechanical stimulation in the
von Frey filament assay, and they do not show any difference in thermal and visceral pain
responses [48]. In our study, under baseline conditions, WT and D2KO animals display similar
overall PWT (Before SNL point in S3A Fig) in the von Frey filament assay. However, after
SNL, D2KO mice develop a faster mechanical allodynia (Day 1 and 3 post SNL points in S3A
Fig). Consequently both genotypes reached a similar level of mechanical sensitivity (Day 7 post
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SNL points in S3A Fig). On the other hand, WT and D2KO animals display similar overall
PWL baseline (Before SNL point in S3B Fig) and a comparable trend in terms of thermal
hyperalgesia development (Day 4 and 8 post SNL points in S3B Fig) in the hot box assay.
In summary, our study demonstrated the effectiveness of Corydalis yanhusuo extract in
three types of pain assays without resulting in development of tolerance. Our study also illus-
trated the mechanism involved in these antinociceptive effects. It is noteworthy that YHS is not
only clinically used for pain management in China, but also is sold as a dietary supplement in
United States. Our current results suggest that YHSmight serve as a candidate for alternative
management of pain.
Supporting Information
S1 Fig. Effects of YHS in locomotor activity and rotarod assays. (A) Effects of YHS (100–500
mg/kg) in Swiss Webster mice assessed in the locomotor activity assay (n = 6–9). One way
ANOVA revealed a significant drug effect (F4,31 = 13.66, P< 0.0001) followed by Dunnett’s
post hoc tests: drug vs vehicle, P< 0.01,  P< 0.001. (B) Effects of YHS (100–500 mg/kg)
in Swiss Webster mice assessed in the rotarod assay (n = 8). One way ANOVA revealed no sig-
nificant drug effect (F3,28 = 0.7925, P = 0.5083). (C) Effects of YHS (100, 200 mg/kg) in 129/sv
mice assessed in the locomotor activity assay (n = 9–10). One way ANOVA revealed no signifi-
cant drug effect (F2,25 = 0.7993, P = 0.4608). (D) Effects of YHS (100, 200 mg/kg) in the mice
used as wild-type control for the D2KO mice assessed in the locomotor activity assay (n =
8–10). One way ANOVA revealed no significant drug effect (F2,24 = 1.167, P = 0.3284). (E)
Effects of YHS (100, 200 mg/kg) in the mice used as wild-type control for the D2KO mice
assessed in the rotarod assay (n = 8). One way ANOVA revealed no significant drug effect
(F3,21 = 0.5191, P = 0.6025)
(TIF)
S2 Fig. The antagonist dose-responsecurve of YHS induced by dopamine in D1 and D2
receptors in D1 and D2 expressing cells.Error bars represent standard error of the mean of
duplicate measurements for each point.
(TIF)
S3 Fig. Neuropathic pain development of WT and D2KO mice. (A) Development of tactile
allodynia of WT and D2KO mice assessed in the von Frey filaments assay (n = 10). Two way
ANOVA revealed significant treatment effects (F3,36 = 11.99, P< 0.0001), time effect (F3,108 =
8.557, P< 0.0001) and treatment x time interaction (F9,108 = 2.451, P = 0.0140) followed by
Bonferroni post hoc test: contralateral vs ipsilateral, P< 0.05,  P< 0.001. (B) Development
of thermal hyperalgeisa of WT and D2KO mice assessed in the hot box assay (n = 10). Two
way ANOVA revealed significant treatment effects (F3,36 = 56.34, P< 0.0001), time effect
(F2,72 = 84.75, P< 0.0001) and treatment x time interaction (F6,72 = 16.90, P< 0.0001) fol-
lowed by Bonferroni post hoc test: contralateral vs ipsilateral,  P< 0.001.
(TIF)
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